HEMOGENYX PHARMACEUTICALS PLC

Director's Dealing • May 1, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6565X

Hemogenyx Pharmaceuticals PLC

01 May 2019

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that it has been advised that on 30 April 2019 Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), purchased 840,336 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 2.38p per share. Following this transaction, Mr Wright now has a total beneficial interest in 840,336 Ordinary Shares, representing approximately 0.23 per cent of the Company's issued share capital.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1.

Details of PDMR/person closely associated with them ("PCA")

a)

Name

Andrew Wright

b)

Position/status

Financial Controller and Company Secretary/PDMR (non-board)

c)

Initial notification/

amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares of 1p of Hemogenyx Pharmaceuticals plc

Identification code GB00BYX3WZ24

b)

Nature of the transaction

Acquisition of ordinary shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
GBP £0.0238	840,336

d)

Aggregated information

-     Aggregated volume

-     Price

Price(s)	Volume(s)
GBP £20,000.00	840,336

e)

Date of the transaction

2019-04-30

f)

Place of the transaction

London Stock Exchange

XLON

Enquiries:

Hemogenyx Pharmaceuticals plc	www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Sir Marc Feldmann, Executive Chairman
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Corporate Finance Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
US Media enquiries
Lowell Goodman	Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHDGGDSDXXBGCG